CTOs on the Move

New York Cancer and Blood Specialists

www.nycancer.com

 
New York Cancer & Blood Specialists is committed to our patients. We are dedicated to providing each patient with a unique path to treatment and unmatched support. We strive to make quality, comprehensive cancer care available to each and every patient throughout New York.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.nycancer.com
  • 1500 Route 112 Building 4
    Port Jefferson Station, NY USA 11776
  • Phone: 631.751.3000

Executives

Name Title Contact Details
Carlos Ng
Vice President of Information Technology Profile
Sean Riley
Chief Information Officer Profile

Similar Companies

Edge Mechanical Systems

Edge Mechanical Systems is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stayma Consulting Services

Stayma Consulting Services is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Care Center

Family Care Center provides counseling, medication management, and TMS. We specialize in mental health care for the entire family. Call today to learn more.

Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate`s product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body`s innate immune system to attack tumors in combination with other therapies.

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.